Abstract: The invention relates to a new process for the preparation of high water affinity type products with controlled humidity via spray drying in a suitable spray drying equipment applying specific spray drying parameters.

Abstract: The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1-R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: Disclosed are novel solid forms of compound (I), (3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid), and pharmaceutical compositions comprising solid forms thereof having characteristics described herein, which can be used as a HBV capsid inhibitor (or HBV Core Protein Allosteric Modifier), or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.

Abstract: Herein is reported the use of RG6035 as a medicament in the treatment of multiple sclerosis, wherein RG6035 is administered at a dose of 140-210 mg.

Abstract: The invention relates to a novel process for the preparation of chiral pyrrolo triazole alcohols of the formula I wherein X is a halogen atom, n is an integer of 1, 2 or 3 and wherein the spiral bond “” stands for “” or for “” or mixtures of the enantiomers. The chiral pyrrolo triazole alcohols of the formula I are versatile intermediates for the preparation of compounds that have the potential to serve as active pharmaceutical ingredients in drugs.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and n are as defined herein, compositions including methods of making the compounds and using the compounds as ATX inhibitors.

Abstract: The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I) wherein R1, R2 and R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The invention provides novel compounds having the general formula I wherein R1, R2, and R3 are as defined herein, compositions including the compounds and methods of using the compounds.

Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: Disclosed herein are processes for the preparation of fused heteroaryl dihydro pyrimidine compounds, or salts or stereoisomers thereof, which are useful for the treatment and prophylaxis of hepatitis B virus infections using compounds of formula IX or stereoisomers thereof, wherein a disclosed process comprises a. reacting a compound formula II with hydrogen in the presence of a solvent and a palladium catalyst or a platinum catalyst, to form a compound of formula III: b. reacting the compound of formula III, or a salt or stereoisomer thereof, with a hydrolase selected from the group consisting of an amidase and a peptidase, or a mixture thereof, to form a compound of formula I: or a salt or stereoisomer thereof, c.

Abstract: The present invention relates to proteins, particularly antibodies such as anti-CD20/anti-CD3 bispecific antibodies and anti ?-synuclein antibodies, having monogalactosylated (G1) and digalactosylated (G2) glycans. More particular, the present invention relates to galactosylation engineering to generate proteins with improved therapeutic properties, including proteins with increased titer. Further, the invention relates to a cell culture medium and a mammalian cell as well as methods using said cell culture medium and said mammalian cell for producing said proteins. Moreover, the present invention relates to the use of said antibodies as a medicament such as for the treatment of cancer, particularly cancer associated with B-cells, or Parkinson's disease.

Abstract: Herein is reported a method for producing recombinant adeno-associated viral particle preparation (rAAVp) comprising the step of cultivating a mammalian cell comprising expression cassettes for a non-adeno-associated viral gene, which is interspaced between two AAV inverted terminal repeats (ITRs), an adeno-associated virus rep gene, an adeno-associated virus cap gene, an adeno-associated virus E1A gene, an adeno-associated virus E1B gene, an adeno-associated virus E2A gene, an adeno-associated virus E4orf6 and an adeno-associated virus VA RNA gene, and thereby producing the rAAVp, wherein the cultivating is at a pH value in the range of and including pH 7.4 to pH 7.6. The yield of the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 is higher than the yield of a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2 and the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.

Abstract: Provided herein are diagnostic and therapeutic methods for the treatment of cancer using polygenic risk scores (PRSs) for liver damage. In particular, the invention provides methods for patient selection and methods of treatment.

Abstract: The present invention relates to systems and methods for analyzing data from motion activity monitoring technology. It is particularly, but not exclusively, concerned with a method for determining motion activity patterns during sleep.

Abstract: The present invention provides new bicyclic tetrahydrothiazepine derivatives having the general formula (I) wherein R1, R2 and R4 are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with proteasome inhibitors. The combination therapy may further comprise a glucocorticosteroid.

Abstract: The present disclosure provides methods of treating a steatotic liver disease associated with metabolic dysfunction, such as metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated fatty livers disease (MAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.

Abstract: The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with CD38 antibodies.

Abstract: The present invention relates to the prevention or mitigation of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of JAK and/or mTOR.